Suppressed microRNA-96 inhibits iNOS expression and dopaminergic neuron apoptosis through inactivating the MAPK signaling pathway by targeting CACNG5 in mice with Parkinson’s disease

Table 2 Behavioral changes at different time points for mice among seven groups

	Number	Before injection	7 d after injection	10 d after injection	12 d after injection	14 d after injection
Normal group	10	8.06 ± 0.71	8.22 ± 0.80	8.17 ± 0.75	8.19 ± 0.86	8.63 ± 0.53
PD group	10	8.46 ± 0.36	6.55 ± 0.63^*	6.05 ± 0.35^*	6.51 ± 0.81^*	7.11 ± 0.68^*
NC group	10	8.39 ± 0.70	6.56 ± 0.71^*	6.09 ± 0.49^*	6.55 ± 0.50^*	7.06 ± 0.81^*
miR-96 mimic group	10	8.07 ± 0.37	4.38 ± 0.74^*#	4.23 ± 0.35^*#	4.27 ± 0.27^*#	5.54 ± 0.62^*#
miR-96 inhibitor group	10	8.11 ± 0.16	3.22 ± 0.71^*#	3.06 ± 0.44^*#	3.19 ± 0.32^*#	4.13 ± 0.59^*#
CACNG5 group	10	8.25 ± 0.21	3.56 ± 0.17^*#	3.41 ± 0.46^*#	3.37 ± 0.18^*#	4.15 ± 0.45^*#
miR-96 mimic + CACNG5 group	10	8.30 ± 0.69	6.36 ± 0.66^*	6.06 ± 0.73^*	6.60 ± 0.78^*	7.03 ± 0.67^*

Note: The test was repeated three times independently, and the one-way ANOVA analysis was used for comparison among multiple groups (n = 10)
PD Parkinson disease, NC Negative control, miR-96 microRNA-96, CACNG5 Calcium voltage-gated channel auxiliary subunit gamma 5, d Day
^*P < 0.05 compared with the normal group, ^#, P < 0.05 compared with the PD group